Next Article in Journal
Change in Hepatitis A Seroprevalence among U.S. Children and Adolescents: Results from the National Health and Nutrition Examination Survey 2003–2006 and 2007–2010
Next Article in Special Issue
Kaiser Permanente Vaccine Study Center: Highlights of 2009–2012
Previous Article in Journal / Special Issue
A Threat- and Efficacy-Based Framework to Understand Confidence in Vaccines among the Public Health Workforce
Vaccines 2013, 1(2), 88-104; doi:10.3390/vaccines1020088
Article

Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women

1,2,* , 1, 1, 3, 3, 4 and 1,5
Received: 31 January 2013; in revised form: 1 March 2013 / Accepted: 25 March 2013 / Published: 8 April 2013
(This article belongs to the Special Issue Confidence in Vaccines)
View Full-Text   |   Download PDF [539 KB, uploaded 8 April 2013]
Abstract: An HIV vaccine, once it becomes available, could reduce vulnerability to HIV among African-American women. The purpose of this study was to assess determinants of HIV vaccine acceptability among African-American women across hypothetical levels of vaccine efficacy. Participants were recruited from a hospital-based family planning clinic in Atlanta, GA serving low-income patients (N = 321). Data were collected from audio-computer assisted surveys administered in the clinic waiting room. Psychosocial survey items were guided by Risk Homeostasis Theory (RHT) and Social Cognitive Theory (SCT). Multivariate logistic regression was used to identify determinants of acceptability for two hypothetical HIV vaccines with 50% and 90% efficacy. Overall, 63% of participants would accept a vaccine with 50% efficacy and 85% would accept a vaccine with 90% efficacy. In multivariate analyses, odds of acceptability for a vaccine with 50% efficacy were higher among participants with greater perceived HIV vaccine benefits (AOR = 1.13, p < 0.001) and lower among participants with more than high school education (AOR = 0.47, p = 0.033) and greater perceived costs of HIV vaccination (AOR = 0.95, p = 0.010). Odds of acceptability for a vaccine with 90% efficacy were higher among participants with greater perceived costs of unprotected sex (AOR = 1.08, p = 0.026), HIV vaccine benefits (AOR = 1.23, p < 0.001) and self-efficacy for sex refusal (AOR = 1.11, p = 0.044). HIV vaccine acceptability was high, particularly for a vaccine with 90% efficacy. Findings suggest that demographic and psychosocial factors may impact acceptability of an eventual HIV vaccine. Once an HIV vaccine is available, interventions to maximize uptake may benefit from using RHT and SCT constructs to target relevant psychosocial factors, such as perceived benefits and perceived costs of vaccination.
Keywords: HIV vaccine; women; attitudes; acceptability; behavioral theory HIV vaccine; women; attitudes; acceptability; behavioral theory
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Painter, J.; Cene-Kush, C.; Conner, A.; Cwiak, C.; Haddad, L.; Mulligan, M.; DiClemente, R. Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women. Vaccines 2013, 1, 88-104.

AMA Style

Painter J, Cene-Kush C, Conner A, Cwiak C, Haddad L, Mulligan M, DiClemente R. Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women. Vaccines. 2013; 1(2):88-104.

Chicago/Turabian Style

Painter, Julia; Cene-Kush, Clare; Conner, Alaina; Cwiak, Carrie; Haddad, Lisa; Mulligan, Mark; DiClemente, Ralph. 2013. "Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women." Vaccines 1, no. 2: 88-104.


Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert